Haematologica (Apr 2020)
Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients
- Junji Tanaka,
- Norina Tanaka,
- Yan-Hua Wang,
- Kenjiro Mitsuhashi,
- Michiko Ryuzaki,
- Yuki Iizuka,
- Aya Watanabe,
- Midori Ishiyama,
- Akihito Shinohara,
- Hiroshi Kazama,
- Shotaro Hagiwara,
- Kentaro Yoshinaga,
- Yumi Kougen,
- Hirohito Kobayashi,
- Hitoshi Kanno,
- Masayuki Shiseki
Affiliations
- Junji Tanaka
- Department of Hematology
- Norina Tanaka
- Department of Hematology
- Yan-Hua Wang
- Department of Hematology
- Kenjiro Mitsuhashi
- Department of Hematology
- Michiko Ryuzaki
- Department of Hematology
- Yuki Iizuka
- Department of Hematology
- Aya Watanabe
- Department of Hematology
- Midori Ishiyama
- Department of Hematology
- Akihito Shinohara
- Department of Hematology
- Hiroshi Kazama
- Department of Hematology
- Shotaro Hagiwara
- Department of Hematology
- Kentaro Yoshinaga
- Department of Hematology
- Yumi Kougen
- Department of Transfusion Medicine and Cell Processing, Tokyo Women’s Medical University, Tokyo, Japan
- Hirohito Kobayashi
- Department of Transfusion Medicine and Cell Processing, Tokyo Women’s Medical University, Tokyo, Japan
- Hitoshi Kanno
- Department of Transfusion Medicine and Cell Processing, Tokyo Women’s Medical University, Tokyo, Japan
- Masayuki Shiseki
- Department of Hematology
- DOI
- https://doi.org/10.3324/haematol.2019.226696
- Journal volume & issue
-
Vol. 105,
no. 4
Abstract
No abstracts available.
